Youngjun Kim
Clinical Pharmacology · Cypress, CANPI 1235661646
Payments from drug & device makers
Across 67 payments — averaging $189,146 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7.3M
- E.r. Squibb & Sons, L.L.C.$3M
- Genentech, Inc.$1.4M
- Novo Nordisk AS$609K
- Arcutis Biotherapeutics, Inc.$188K
- Takeda Pharmaceuticals U.S.A., Inc.$75K
- plus $93K from 3 others
Across 2 payments — averaging $5341.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$11K
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 23 | $7,296,184 |
| E.r. Squibb & Sons, L.L.C. | 13 | $2,970,415 |
| Genentech, Inc. | 13 | $1,440,688 |
| Novo Nordisk AS | 9 | $608,854 |
| Arcutis Biotherapeutics, Inc. | 3 | $188,198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $75,264 |
| Cidara Therapeutics, Inc. | 2 | $47,524 |
| Biogen | 1 | $44,082 |
| Novartis | 1 | $1,578 |
How this compares
Too few clinical pharmacology providers in Californiato place this figure against a meaningful peer group, so we don't.
Other clinical pharmacology in Cypress
- Jeffrey KittrelleSan Diego$261K
- Carl PeckSan Luis Obispo$34K
- Ferre' AkbarpourHuntington Beach$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.